Novo Nordisk Initiates Phase 3 Head-to-Head Trial of CagriSema vs. Tirzepatide for Obesity Treatment

On November 14, 2023, Novo Nordisk registered on the Clinicaltrials.gov website.CagriSemaPhase III Clinical Trial of Tirzepatide Head-to-Head for Weight Loss.

This Phase III clinical trial plans to enroll 800 patients who are obese or overweight, with an expected completion date of August 2025.

Patients will receive treatment with 2.4mg Cagrilintide + 2.4mg Semaglutide or Tirzepatide at a high dose of 15mg.

Novo Nordisk has conducted multiple Phase III clinical trials for CagriSema in type 2 diabetes and weight loss indications.

CagriSema shows significantly improved weight loss and blood sugar reduction effects compared to semaglutide alone.

CagrilintideAs an amylin analog, it is a natural peptide related to dietary metabolism, which can induce a sense of fullness, thereby reducing food and energy intake.

Summary

Novo Nordisk's iterative innovation in the diabetes field continues to lead globally, with the first once-a-week insulin commercialization on the horizon. In the GLP-1 field, Eli Lilly has more advantages, particularly in dual-target mechanisms.TirzepatideDefeating Semaglutide and already approved for marketing, small-molecule GLP-1R agonists and GLP-1R/GIPR/GCGR triple-target agonists have entered the Phase III clinical stage. However, Novo Nordisk's combination therapy of Semaglutide + Cagrilintide can compete with Eli Lilly's dual-target and triple-target drugs, while oral Semaglutide can compete with small-molecule GLP-1R (although small molecules have a clear cost advantage in this regard). In terms of indication expansion, in addition to lowering blood sugar and weight loss, Novo Nordisk is also actively exploring AD, NASH,Heart FailureAnd other new fields.